- Home
- FREY vs STRO Comparison
FREY vs STRO Comparison
Compare FREY & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FREY
- STRO
- Stock Information
- Founded
- FREY 2018
- STRO 2003
- Country
- FREY Luxembourg
- STRO United States
- Employees
- FREY N/A
- STRO N/A
- Industry
- FREY Industrial Machinery/Components
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FREY Miscellaneous
- STRO Health Care
- Exchange
- FREY Nasdaq
- STRO Nasdaq
- Market Cap
- FREY 364.9M
- STRO 172.8M
- IPO Year
- FREY N/A
- STRO 2018
- Fundamental
- Price
- FREY $2.98
- STRO $1.93
- Analyst Decision
- FREY
- STRO Strong Buy
- Analyst Count
- FREY 0
- STRO 7
- Target Price
- FREY N/A
- STRO $12.14
- AVG Volume (30 Days)
- FREY 3.0M
- STRO 1.4M
- Earning Date
- FREY 11-06-2024
- STRO 11-13-2024
- Dividend Yield
- FREY N/A
- STRO N/A
- EPS Growth
- FREY N/A
- STRO N/A
- EPS
- FREY N/A
- STRO N/A
- Revenue
- FREY N/A
- STRO $160,955,000.00
- Revenue This Year
- FREY N/A
- STRO N/A
- Revenue Next Year
- FREY $414.23
- STRO N/A
- P/E Ratio
- FREY N/A
- STRO N/A
- Revenue Growth
- FREY N/A
- STRO 230.90
- 52 Week Low
- FREY $0.91
- STRO $1.70
- 52 Week High
- FREY $3.00
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- FREY 75.91
- STRO 29.88
- Support Level
- FREY $1.56
- STRO $1.70
- Resistance Level
- FREY $2.17
- STRO $3.01
- Average True Range (ATR)
- FREY 0.25
- STRO 0.21
- MACD
- FREY 0.10
- STRO -0.02
- Stochastic Oscillator
- FREY 98.62
- STRO 17.56
About FREY FREYR Battery Inc.
FREYR Battery Inc is an emerging producer of clean battery solutions for the planet. It designs and manufactures high-density and cost-competitive lithium-ion batteries with a reduced carbon footprint for the markets for electric mobility, stationary energy storage, and marine and aviation applications.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.